Drugmakers Rush to Test New Ebola Vaccine

While developing drugs to cure Ebola is crucial to end the current epidemic, a vaccine that prevents the infection altogether is the end-game for viral outbreaks – a way to protect healthcare workers on the front lines and to prevent future outbreaks.

It typically takes 10 or 20 years to develop and test a vaccine and get it to market. But in Ebola’s case, this time frame has been compressed into a matter of months, bringing pharmaceutical companies, scientists and regulators into uncharted territory, striving for a vaccine to curb the still-escalating epidemic without compromising safety.

“Never before has there been a push to develop a vaccine for an emerging public health threat in this short a time frame,” said Dr. Mark Feinberg, vice president and chief public health and science officer of the drug company Merck’s vaccine division.

Dr. Ripley Ballou, head of Ebola vaccine research for GlaxoSmithKline, concurs. “I’ve been doing this kind of work for 30 years, and this is the first time I’ve encountered anything with the compressed timeline and sense of urgency,” he said.

In the Pipeline

There are three vaccines currently in significant stages of development, all rushed into drug trials since the Ebola outbreak started… (read more)